Aav5
Aav5 - Related Videos
14:49
A Quantitative Dot Blot Assay for AAV Titration and Its Use for Functional Assessment of the Adeno-associated Virus Assembly-activating Proteins
0 Views •
Cited by 3 •
2018
This manuscript details a straightforward dot blot assay for quantitation of adeno-associated virus (AAV) titers and its application to study the role of assembly-activating proteins (AAPs), a novel class of non-structural viral proteins found in all AAV serotypes, in promoting the assembly of capsids derived from cognate and heterologous AAV serotypes.
10:14
Using Adeno-associated Virus as a Tool to Study Retinal Barriers in Disease
0 Views •
Cited by 7 •
2015
To investigate the blood-retinal barrier permeability and the inner limiting membrane integrity in animal models of retinal disease, we used several adeno-associated virus (AAV) variants as tools to label retinal neurons and glia. Virus mediated reporter gene expression is then used as an indicator of retinal barrier permeability.
12:26
In Vivo Direct Reprogramming of Resident Glial Cells into Interneurons by Intracerebral Injection of Viral Vectors
0 Views •
Cited by 8 •
2019
This protocol aims at generating directly reprogrammed interneurons in vivo, using an AAV-based viral system in the brain and a FLEX synapsin-driven GFP reporter, which allows for cell identification and further analysis in vivo.
FAQs
Capsid binding to cell-surface glycans is an early determinant of cellular entry and contributes to the vector’s tissue tropism. Because AAV5 has a distinct tropism, investigators consider how efficiently it can access tissues such as the liver, nervous system, or eye. This relationship helps guide vector selection and interpretation of tissue-specific delivery outcomes.
Persistence of the vector genome as episomal DNA in the nucleus is important when evaluating how therapeutic expression may be maintained after delivery. Researchers therefore assess genome persistence alongside expression, dose, and tissue distribution. These measurements help characterize durability and support decisions about whether a given AAV5 design is suitable for a particular disease context.
Replacing the viral rep and cap genes creates space for a therapeutic expression cassette while allowing the AAV5 capsid to serve as the delivery shell. This arrangement separates the genetic material intended for treatment from the genes used to produce the vector. The design is central to constructing recombinant systems for medical investigation.
AAV5’s tissue preference and immunological characteristics influence how researchers evaluate candidate vectors. These properties are considered when selecting target organs, estimating dose, assessing safety, and planning immune-response management. They also help explain why the same vector platform may be investigated differently for diseases affecting the liver, nervous system, eye, or other tissues.
Evaluation generally connects vector design with biological and safety testing. Investigators select a therapeutic expression cassette, use the AAV5 capsid for delivery, and examine tissue tropism, nuclear genome persistence, dose-related behavior, safety, and immune responses. Together, these assessments determine whether the vector’s delivery characteristics and risk profile support further medical research.
AAV5 is investigated in both inherited and acquired diseases, with particular relevance to applications involving the liver, nervous system, and eye. Its use in these areas reflects the combination of tissue tropism, nuclear delivery, and a distinct immunological profile. Research outcomes can inform therapeutic development as well as broader principles of vector design and dose selection.